UK to Launch Gonorrhea Vaccination Program Amid Rising STI Cases

Fri 30th May, 2025

The National Health Service (NHS) in the UK is set to introduce a new vaccination program aimed at combating gonorrhea, making England and Wales the first regions globally to implement such an initiative.

This decision comes in response to a significant surge in gonorrhea infections in England, which saw over 85,000 diagnoses in 2023 alone. This figure marks a staggering 234% increase from the 25,525 cases reported in 2012.

Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is the second most prevalent sexually transmitted infection (STI) in the UK. It is primarily transmitted through unprotected sexual contact with an infected individual. Alarmingly, approximately 10% of men and nearly half of women infected with gonorrhea do not exhibit any symptoms, contributing to its rapid spread, as asymptomatic individuals may not seek testing or treatment.

For those who do show symptoms, common signs include unusual discharge, painful urination, and discomfort in the lower abdomen. If left untreated, gonorrhea can result in severe complications such as infertility and pelvic inflammatory disease in women and epididymitis in men.

Current methods of treatment for gonorrhea primarily involve antibiotics; however, rising antibiotic resistance has complicated treatment efforts. As a result, the introduction of a vaccine is seen as a crucial step in prevention.

The forthcoming vaccination program will utilize an existing childhood vaccine known as 4CMenB (marketed as Bexsero). This vaccine is typically administered to protect against meningococcal group B disease, which can lead to severe bacterial meningitis and sepsis. Notably, the bacterium responsible for gonorrhea shares a significant genetic relationship with the bacteria that causes meningococcal disease, with their genomes exhibiting 80% to 90% similarity.

The 4CMenB vaccine comprises four antigens aimed at combating Neisseria meningitidis. When administered, these antigens trigger an immune response, prompting the body to produce antibodies that neutralize the bacteria. Research indicates that two of the antigens present in the 4CMenB vaccine are also found in both the gonorrhea and meningococcal bacteria, which supports the vaccine's potential effectiveness against gonorrhea.

Studies have suggested that the 4CMenB vaccine can provide some level of protection against gonorrhea, with effectiveness rates ranging from 32% to 42%. Although this does not guarantee complete immunity, it significantly lowers the risk of contraction and reduces the chances of transmitting the infection to others.

The primary advantage of the vaccination program will be a notable decrease in gonorrhea cases, particularly given the challenges posed by antibiotic resistance. It is essential to note that past infections do not confer immunity against future infections, underscoring the vaccine's importance even with moderate efficacy.

The vaccination initiative will target high-risk groups, including gay and bisexual men with a history of multiple sexual partners or previous STIs. Starting in early August 2025, eligible individuals will be identified through local sexual health services and a broader public awareness campaign. Those receiving the gonorrhea vaccine will also be offered vaccinations for mpox, hepatitis A and B, and human papillomavirus at the same time.

Investing in the vaccination of at-risk populations is expected to be more cost-effective than focusing solely on treatment for those already diagnosed with gonorrhea. Projections from Imperial College London suggest that the 4CMenB vaccine could prevent up to 100,000 gonorrhea cases and save the NHS over £7.9 million in the next decade, provided a high uptake is achieved.


More Quick Read Articles »